Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “acquire” rating to a “hold” ranking in a research note provided to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on discovering and developing tiny molecule medicine candidates to treat cancer cells. The Business‘s items under different stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts also just recently commented on the firm. Noble Financial reissued a “buy” ranking and also provided a $11.00 cost purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving ordinary rate of $2.90 and a two-hundred day relocating ordinary rate of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, covering analysts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an unfavorable net margin of 8,294.27%. The company had income of $0.06 million during the quarter, compared to the consensus quote of $0.06 million. Throughout the very same quarter in the previous year, the firm posted ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will publish -1.18 EPS for the current year.

A variety of hedge funds have actually just recently dealt shares of ONTX. GSA Funding Partners LLP acquired a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Funding Management LP got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional capitalists possess 13.36% of the firm’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and also advancement of oncology therapeutics. It concentrates on discovering and creating little particle medicine prospects to deal with cancer cells. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a cost-free copy of the Zacks research report on Onconova Therapeutics (ONTX).

For more details regarding research offerings from Zacks Investment Research, visit Zacks.com.

This instant news alert was created by narrative science innovation and also monetary information from Market in order to provide viewers with the fastest and also most accurate coverage. This tale was evaluated by Market’s editorial group before publication. 



Before you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market tracks Wall Street’s premier as well as best performing research analysts and the stocks they suggest to their clients every day. Market has determined the five stocks that cover experts are silently murmuring to their customers to get now before the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics presently has a “Buy” score among experts, premier experts believe these five stocks are better acquires.